The Technical Analyst
Corbus Pharmaceuticals [CRBP]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Corbus Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-1.70% $36.53
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 383.31 mill |
| EPS: | -10.31 |
| P/E: | -3.54 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 10.49 mill |
| Avg Daily Volume: | 0.978 mill |
| RATING 2024-04-18 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.54 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.60x |
| Company: PE -3.54 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-1.610 (-104.41%) $-38.14 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 32.35 - 40.71 ( +/- 11.45%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-10 | Moran Sean F. | Buy | 1 787 | Common Stock |
| 2024-04-10 | Moran Sean F. | Sell | 1 787 | Employee Stock Option (right to buy) |
| 2024-03-08 | Cormorant Asset Management, Lp | Buy | 8 862 | Common Stock |
| 2024-03-08 | Cormorant Asset Management, Lp | Buy | 156 597 | Common Stock |
| 2024-03-08 | Cormorant Asset Management, Lp | Buy | 61 668 | Common Stock |
| INSIDER POWER |
|---|
| 99.57 |
| Last 95 transactions |
| Buy: 14 080 389 | Sell: 365 661 |
Forecast:
16:00 - $36.48
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $36.48
Forecast 2: 16:00 - $36.48
Forecast 3: 16:00 - $36.48
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $36.53 (-1.70% ) |
| Volume | 0.128 mill |
| Avg. Vol. | 0.978 mill |
| % of Avg. Vol | 13.06 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CRBP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $22.05 | N/A | Active |
|---|
CRBP
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Latest Press Releases
2024-04-02 08:00:00 - Press Release
Corbus Announces Dosing Of First Patient In U.s. Phase 1 Clinical Trial Of Its Next Generation Nectin-4 Targeting Adc
Norwood, mass., april 02, 2024 (globe newswire) -- corbus pharmaceuticals holdings, inc. (nasdaq: crbp) (“corbus” or the “company”), a precision oncology company with a diversified portfolio, announced today the first patient in the u.s. has been dosed in the phase 1 clinical trial of crb-701 (sys6002), a next-generation antibody-drug-conjugate (adc) targeting nectin-4.
2024-03-12 08:00:00 - Press Release
Corbus Pharmaceuticals Reports Fourth Quarter And Year-end 2023 Financial Results And Provides Corporate Update
Norwood, mass., march 12, 2024 (globe newswire) -- corbus pharmaceuticals holdings, inc. (nasdaq: crbp) (“corbus” or the “company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the fourth quarter of 2023 and year-ended 2023.
2024-03-06 08:00:00 - Press Release
Corbus Pharmaceuticals To Participate In The Bmo Capital Markets Inaugural Obesity Summit
Norwood, mass., march 06, 2024 (globe newswire) -- corbus pharmaceuticals holdings, inc. (nasdaq: crbp) (“corbus” or the “company”), today announced that yuval cohen, ph.d., chief executive officer of corbus, will participate in a panel discussion at bmo capital markets inaugural bmo obesity summit to be held on march 20, 2024 in new york city, ny.
2024-02-28 08:00:00 - Press Release
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst As Chief Medical Officer
Norwood, mass., feb. 28, 2024 (globe newswire) -- corbus pharmaceuticals holdings, inc. (nasdaq: crbp) (“corbus” or the “company”), a precision oncology company with a diversified portfolio, today announced the appointment of dr. dominic smethurst, ma mrcp, as the company's chief medical officer (cmo). in this role, dr. smethurst will lead the clinical development of the company's investigational oncology drugs: crb-701, a next generation nectin-4 targeting antibody drug conjugate (adc) developed in partnership with cspc, and crb-601, a tgfΒ blocking monoclonal antibody targeting the integrin ΑvΒ8. additionally, dr. smethurst will help guide strategic development of crb-913, the company's highly peripherally restricted cb1 inverse agonist for the treatment of obesity.
2024-02-06 09:50:00 - Press Release
Corbus Pharmaceuticals To Present At The Oppenheimer 34th Annual Healthcare Life Sciences Conference
Norwood, mass., feb. 06, 2024 (globe newswire) -- corbus pharmaceuticals holdings, inc. (nasdaq: crbp) (“corbus” or the “company”), today announced that yuval cohen, ph.d., chief executive officer of corbus, will provide a corporate update and participate in one-on-one investor meetings at the oppenheimer 34th annual healthcare life sciences conference, to be held virtually february 13-14, 2024.
Latest News
2024-03-17 09:10:54 - 24/7 Wall Street
Buffett Can't Get Enough of This Stock, Plus Other Insider Buying
The Oracle of Omaha has once more bolstered his stake in a media giant's tracking stocks.
2024-03-15 09:51:08 - Zacks Investment Research
What Makes Corbus Pharmaceuticals (CRBP) a Good Fit for 'Trend Investing'
If you are looking for stocks that are well positioned to maintain their recent uptrend, Corbus Pharmaceuticals (CRBP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
2024-03-08 20:02:59 - InvestorPlace
All Three of Our Analysts Agree
2024-02-06 09:50:00 - GlobeNewsWire
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
NORWOOD, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024.
2024-02-05 08:40:08 - MarketBeat
Corbus Pharmaceuticals stock: An explosive 342% YTD surge
Shares of Corbus Pharmaceuticals NASDAQ: CRBP have already experienced a meteoric rise of over 300% year-to-date. This is thanks to fresh news released two Fridays ago, on January 26.
2024-01-29 14:17:45 - Seeking Alpha
Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark Clouds
Corbus Pharmaceuticals has experienced a surge in stock price after positive clinical results for their antibody drug conjugate, CRB-701. CRBP is conducting phase 1 studies for CRB-701 in patients with Nectin-4-positive solid tumors, showing favorable tolerability and promising efficacy. The company's financial situation is concerning, with limited cash on hand and the need for significant financing to continue operations.
2024-01-29 07:18:08 - Invezz
Corbus Pharmaceuticals (CRBP) is up 250%: what's up with the stock?
The stock of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) closed up nearly 250% last week. The gains happened after favourable pharmaceutical news that saw the stock climb above $29.
2024-01-26 14:19:11 - InvestorPlace
Why Is Corbus Pharmaceuticals (CRBP) Stock Up 300% Today?
Shares of little-known Corbus Pharmaceuticals (NASDAQ: CRBP ) are absolutely skyrocketing today. At the time of writing, CRBP stock is up more than 300%, as investors price in a key announcement from the company.
2023-12-01 11:20:10 - Zacks Investment Research
Is Corbus Pharmaceuticals (CRBP) Stock Outpacing Its Medical Peers This Year?
Here is how Corbus Pharmaceuticals (CRBP) and CVRx (CVRX) have performed compared to their sector so far this year.
2023-09-27 09:05:00 - PRNewsWire
Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
NORWOOD, Mass. , Sept. 27, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that an abstract highlighting pre-clinical data on its CRB-601 anti-aVb8 integrin monoclonal antibody has been accepted for presentation as a poster at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), to be in San Diego, CA November 1-5, 2023.